ARS Pharmaceuticals (SPRY) Research & Development (2022 - 2025)
Historic Research & Development for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to $2.8 million.
- ARS Pharmaceuticals' Research & Development fell 3780.24% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.8 million, marking a year-over-year decrease of 3603.75%. This contributed to the annual value of $19.6 million for FY2024, which is 338.5% down from last year.
- According to the latest figures from Q3 2025, ARS Pharmaceuticals' Research & Development is $2.8 million, which was down 3780.24% from $4.0 million recorded in Q2 2025.
- ARS Pharmaceuticals' 5-year Research & Development high stood at $7.3 million for Q2 2023, and its period low was $2.8 million during Q3 2025.
- Over the past 4 years, ARS Pharmaceuticals' median Research & Development value was $4.4 million (recorded in 2022), while the average stood at $4.5 million.
- As far as peak fluctuations go, ARS Pharmaceuticals' Research & Development skyrocketed by 6800.0% in 2023, and later tumbled by 4359.95% in 2025.
- Over the past 4 years, ARS Pharmaceuticals' Research & Development (Quarter) stood at $4.7 million in 2022, then fell by 27.73% to $3.4 million in 2023, then dropped by 11.08% to $3.0 million in 2024, then dropped by 9.12% to $2.8 million in 2025.
- Its Research & Development was $2.8 million in Q3 2025, compared to $4.0 million in Q2 2025 and $3.0 million in Q1 2025.